Dashboard
PDUFA
PDUFA History
Dilution Watch
Downside Radar
Missed Milestones
Earnings
Big Movers
Blog
🎤 Upcoming Biotech Conferences
Loading conferences...
Free to browse, no account needed
Track neurology and CNS catalysts with approval-probability scores and free alerts.
Neurology & CNS Biotech Pipeline: Brain and Nervous System Drugs
Every neurology and CNS program BioRadar tracks across 135 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 418 neurology and CNS drug programs across 135 public companies, with 4 upcoming FDA decisions in this area. The most active companies by program count are BIIB, ALKS, UTHR, SUPN, AXSM.
418Drug programs
135Companies
132In Phase 3
4Upcoming FDA dates
Upcoming FDA decisions in Neurology & CNS
Companies with neurology and CNS programs
BIIB
32 programs
ALKS
22 programs
UTHR
12 programs
SUPN
10 programs
AXSM
9 programs
CYTK
9 programs
ACAD
8 programs
BMY
8 programs
VYGR
8 programs
WVE
8 programs
IONS
7 programs
NERV
7 programs
TNXP
7 programs
AQST
6 programs
ARGX
6 programs
AVXL
6 programs
BHVN
6 programs
BLRX
6 programs
DNLI
6 programs
PRAX
6 programs
TAK
6 programs
ACIU
5 programs
ALNY
5 programs
AZN
5 programs
BTAI
5 programs
KYTX
5 programs
NBIX
5 programs
VRTX
5 programs
AMGN
4 programs
IMUX
4 programs
LLY
4 programs
RGEN
4 programs
TGTX
4 programs
VNDA
4 programs
ABOS
3 programs
ALEC
3 programs
ANVS
3 programs
CATX
3 programs
CLNN
3 programs
CORT
3 programs
GANX
3 programs
ICLR
3 programs
INDV
3 programs
LBRX
3 programs
MPLT
3 programs
NVS
3 programs
OKYO
3 programs
OPK
3 programs
PRTA
3 programs
SNY
3 programs
TLSA
3 programs
VTVT
3 programs
ABBV
2 programs
ADXN
2 programs
AKBA
2 programs
AMLX
2 programs
AMRX
2 programs
ANRO
2 programs
DRUG
2 programs
DWTX
2 programs
EVMN
2 programs
GHRS
2 programs
IGC
2 programs
IMTX
2 programs
IMVT
2 programs
IPHA
2 programs
JAZZ
2 programs
LGND
2 programs
LNTH
2 programs
LONA
2 programs
MNOV
2 programs
NKTX
2 programs
NRSN
2 programs
PTCT
2 programs
SER
2 programs
TEVA
2 programs
TVTX
2 programs
XENE
2 programs
ZLAB
2 programs
ACOG
1 program
AEON
1 program
ALZN
1 program
AMRN
1 program
APUS
1 program
ARWR
1 program
ASPE
1 program
ATRA
1 program
BHC
1 program
BIVI
1 program
BMRN
1 program
BNTX
1 program
CABA
1 program
CGTX
1 program
CMMB
1 program
CMPS
1 program
CMPX
1 program
COYA
1 program
CRBP
1 program
CTNM
1 program
EXEL
1 program
FBLG
1 program
GOSS
1 program
GRFS
1 program
HELP
1 program
HRMY
1 program
INMB
1 program
IRLA
1 program
JUNS
1 program
KRYS
1 program
LEGN
1 program
LGVN
1 program
LPCN
1 program
LXEO
1 program
LXRX
1 program
MGNX
1 program
MOLN
1 program
NMRA
1 program
NTLA
1 program
OGN
1 program
OMER
1 program
PLYX
1 program
PMN
1 program
QGEN
1 program
QURE
1 program
RAPP
1 program
RARE
1 program
REGN
1 program
RXRX
1 program
SRPT
1 program
TKNO
1 program
VKTX
1 program
VTGN
1 program
XTLB
1 program
ZBIO
1 program
ZURA
1 program
Phase 3 neurology & cns programs (132)
| Ticker | Drug | Indication |
|---|---|---|
| ACAD | ACP-204 | Alzheimer's Disease Psychosis |
| ACAD | Pimavanserin tartrate (ACP-103) | Parkinson's Disease Psychosis |
| ACAD | pimavanserin tartrate | Parkinson's Disease Psychosis |
| ADXN | Dipraglurant | Parkinson Disease |
| ALEC | Latozinemab | Neurodegenerative Diseases |
| ALKS | ALKS 2680 Dose 2 | Narcolepsy Type 1 |
| ALKS | ALKS 2680 Dose 1 | Narcolepsy Type 1 |
| ALKS | ALKS 2680 Dose 3 | Narcolepsy Type 2 |
| ALKS | OLZ/SAM | Schizophrenia |
| ALKS | Olanzapine | Schizophrenia |
| ALKS | ALKS 2680, 4mg | Narcolepsy Type 1 |
| ALKS | ALKS 2680, 18mg | Narcolepsy Type 1 |
| ALKS | ALKS 2680, 10mg | Narcolepsy Type 1 |
| ALKS | ALKS 2680, 6mg | Narcolepsy Type 1 |
| ALKS | ALKS 2680, 14mg | Narcolepsy Type 1 |
| ALKS | ALKS 2680, 8mg | Narcolepsy Type 1 |
| ALKS | ALKS 3831 | Schizophrenia |
| ALKS | ALKS 8700 | Multiple Sclerosis |
| ALKS | Paliperidone Palmitate | Schizophrenia |
| ALKS | Dimethyl Fumarate | Relapsing Remitting Multiple Sclerosis |
| ALNY | Nucresiran | Hereditary Transthyretin-Mediated Amyloidosis With |
| ALNY | Vutrisiran | Hereditary Transthyretin-Mediated Amyloidosis With |
| AMGN | Erenumab Dose 1 | Migraine |
| AMGN | Erenumab Dose 2 | Migraine |
| AMGN | Erenumab Dose 3 | Migraine |
| AMLX | AMX0035 | Progressive Supranuclear Palsy |
| AMRN | Ethyl-EPA (Miraxion™) | Huntington Disease |
| AMRX | Asenapine Sublingual Tablets 10 mg | Schizophrenia |
| ANVS | buntanetap/posiphen | Early Alzheimers Disease |
| APUS | Apitox - pure honeybee toxin | Multiple Sclerosis |
| AQST | Diazepam Buccal Soluble Film 5, 7.5,10, | Epilepsy |
| ARGX | Empasiprubart IV | Chronic Inflammatory Demyelinating Polyneuropathy |
| ARGX | IVIg | Chronic Inflammatory Demyelinating Polyneuropathy |
| ARGX | Empasiprubart | Multifocal Motor Neuropathy (MMN) |
| ARGX | IVIG (Intravenous Immunoglobulin) | Multifocal Motor Neuropathy (MMN) |
| AVXL | ANAVEX2-73 | Alzheimer Disease |
| AVXL | Mid dose ANAVEX2-73 | Alzheimer Disease |
| AVXL | High dose ANAVEX2-73 | Alzheimer Disease |
| AXSM | AXS-07 (MoSEIC meloxicam and rizatriptan | Migraine |
| AXSM | AXS-07 (meloxicam-rizatriptan) | Migraine |
Phase 2 neurology & cns programs (166)
| Ticker | Drug | Indication |
|---|---|---|
| ABBV | MEDI0618 | Migraine |
| ABOS | sabirnetug | Alzheimer Disease |
| ACAD | Active drug: pimavanserin 17mg (2 streng | Parkinson Disease |
| ACAD | ACP-104 | Schizophrenia |
| ACAD | Pimavanserin 34 milligrams (MG) [Nuplazi | Schizophrenia |
| ACAD | Quetiapine | Parkinson's Disease |
| ACIU | ACI-7104.056 at Dose A | Parkinson Disease |
| ACIU | ACI-7104.056 at Dose C (optional) | Parkinson Disease |
| ACIU | ACI-7104.056 at Dose B (optional) | Parkinson Disease |
| ACIU | ACI-35.030 | Alzheimer's Disease |
| ACIU | JACI-35.054 | Alzheimer's Disease |
| ADXN | ADX48621 | Parkinson's Disease |
| AEON | ABP-450 | Migraine |
| AKBA | Praliciguat (Part B) | Focal Segmental Glomerulosclerosis |
| AKBA | Praliciguat (Part A) | Focal Segmental Glomerulosclerosis |
| ALEC | GSK4527226 | Alzheimer's Disease |
| ALEC | AL002 | Alzheimer's Disease |
| ALKS | Samidorphan + olanzapine (ALKS 3831) | Schizophrenia |
| ALKS | Samidorphan (Medium Dose) | Schizophrenia |
| ALKS | Samidorphan (Low Dose) | Schizophrenia |
| ALKS | Samidorphan (High Dose) | Schizophrenia |
| ALNY | Mivelsiran | Down Syndrome-Associated Alzheimer's Disease (DS-A |
| ALZN | ALZN002 (autologous DCs pulsed with E22W | Alzheimer Disease |
| ANRO | ALTO-207 | Treatment-resistant Depression (TRD) |
| ANRO | ALTO-101 | Schizophrenia |
| ANVS | Posiphen | Alzheimer's Disease |
| AQST | Diazepam Buccal Film | Epilepsy |
| AQST | Diazepam Buccal Film 12.5 mg | Epilepsy |
| AQST | Riluzole Oral Soluble film (ROSF) 50 mg | Amyotrophic Lateral Sclerosis |
| AQST | Diastat® Rectal Gel (Valeant Pharmaceuti | Epilepsy |
| AQST | Riluzole Oral Soluble Film | ALS |
| ARGX | ARGX-119 | Amyotrophic Lateral Sclerosis |
| ARWR | ARO-MAPT-SC | Alzheimer Disease |
| ATRA | ATA188 | Primary Progressive Multiple Sclerosis |
| AVXL | ANAVEX3-71 oral capsules | Schizophrenia |
| AVXL | ANAVEX2-73 Oral | Alzheimer's Disease |
| AVXL | ANAVEX2-73 Intravenous | Alzheimer's Disease |
| AZN | SOC | Systemic Sclerosis |
| AZN | AZD0120 | Systemic Sclerosis |
| BHC | Rifaximin SSD 40 mg IR tablet | Dementia Alzheimer Type |
Phase 1 neurology & cns programs (63)
| Ticker | Drug | Indication |
|---|---|---|
| ABOS | sabirnetug (ACU193) | Alzheimer Disease |
| ABOS | ACU193 | Alzheimer Disease |
| ALNY | ALN-HTT02 | Huntington's Disease |
| ALNY | ALN-5288 | Alzheimer's Disease |
| AMLX | AMX0114 | ALS |
| ANVS | Posiphen® tartrate capsules | Alzheimer's Disease |
| ASPE | ANPD001 | Parkinson Disease |
| AXSM | Solriamfetol 150 mg Oral Tablet | Narcolepsy |
| BHVN | BHV-700 | Epilepsy |
| BTAI | BXCL501 60 Micrograms | Schizophrenia |
| BTAI | BXCL501 120 Micrograms | Schizophrenia |
| BTAI | BXCL501 80 Micrograms | Schizophrenia |
| CTNM | PIPE-307 | Multiple Sclerosis |
| CYTK | Moxifloxacin | QT Intervals Changes |
| DNLI | DNL921 | Alzheimer's Disease |
| DNLI | DNL628 | Alzheimer Disease, Early Onset |
| DNLI | DNL747 | Amyotrophic Lateral Sclerosis |
| GANX | GT-02287 | Parkinson Disease |
| GOSS | GB5121 | CNS Lymphoma |
| HRMY | HBS-201 | Narcolepsy |
| IGC | IGC AD1 | Dementia of Alzheimer Type |
| IONS | ION269 | Alzheimer Disease |
| IONS | BIIB094 | Parkinson's Disease |
| IONS | IONIS MAPTRx | Mild Alzheimer's Disease |
| KYTX | KYV-101 (Biological) - 0.33 ×10^8 cells | Progressive Multiple Sclerosis |
| KYTX | Chemotherapy: fludarabine (FLU) | Progressive Multiple Sclerosis |
| KYTX | Chemotherapy: cyclophosphamide (CYC) | Progressive Multiple Sclerosis |
| KYTX | KYV-101 (Biological) - 1 ×10^8 cells | Progressive Multiple Sclerosis |
| LEGN | LCAR-AIO T cells | Multiple Sclerosis (MS) |
| LLY | LY4256984 | ALS (Amyotrophic Lateral Sclerosis) |
| LLY | LY4405094 | Alzheimer Disease |
| LONA | NDX-1017 | Alzheimer Disease |
| NERV | Olanzapine 10 MG | Negative Symptoms in Schizophrenia |
| NMRA | NMRA-323511 | Alzheimer's Disease |
| NVS | XEP527 | Schizophrenia |
| PMN | PMN310 | Alzheimer Disease, Early Onset |
| PRTA | PRX002 | Parkinson's Disease |
| RGEN | RG2077 (CTLA4-IgG4m) | Multiple Sclerosis |
| SER | SER-252 (PEOZ-apomorphine) | PARKINSON DISEASE (Disorder) |
| SER | SER-214 | Parkinson's Disease |
Track neurology and CNS catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a neurology and CNS watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →